(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and disadvantages of these varied drugs and their mode of administration. Based on historical results with these agents when used alone, they also present a rationale for their results when used in combination with other agents.
Contents:
Relative Role of 5-Fluorouracil Activation and Inactivation Pathways on its Cytotoxic Effects: Preclinical and Clinical Modulation
G. J. Peters
Dihydropyrimidine Dehydrogenase and Treatment by Fluoropyrimidines: Past and Future Directions
Gerard Milano
Biochemical Bases of the 5-Fluorouracil-Folinic Acid Interaction and of its Limitations: A Retrospective Analysis
Richard G. Moran
Molecular Mechanisms Regulating the Expression of Thymidylate Synthase
John C. Schmitz, Ashwin Gollerkeri, Xiukun Lin, Jun Liu, and Edward Chu
Regulation of Thymidylate Synthase Gene Expression and Drug Response: Posttranscriptional Regulation and Cell Population Density
Bruce J. Dolnick
Death Receptor Signaling in the Mechanism of 5-Fluorouracil Action
Janet A. Houghton
Circadian Rhythms in 5-Fluorouracil Pharmacology and Therapeutic Applications
Francis Levi
Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents
Alberto F. Sobrero and Ornella Belvedere
Noninvasive Studies of Fluoropyrimidines
Walter Wolf, Cary A. Presant, and Victor Waluch
Comparative Antitumor Activity of 5-Fluorouracil (5-FU) Prodrugs in Preclinical Model Systems: Role of Leucovorin and Dihydropyrimidine Dehydrogenase Inhibitors
Shousong Cao, Gunnar Hapke, and Youcef M. Rustum
Bimonthly 48-h Leucovorin and 5-Fluorouracil-Based Regimens in Advanced Colorectal Cancer
Aimery de Gramont and Christophe Louvet
Review on the Combination of Systemic and Locoregional Treatment for Colorectal Liver Metastases
Roberto Labianca, Gianfranco Pancera, Marinella Mastore, Marina Garassino, Giordano D. Beretta, Paola Poletti, and M. Adelaide Pessi
Fluoropyrimidines in Advanced Colorectal Cancer: A Review of Six Consecutive Meta-Analyses
Pascal Piedbois and Marc E. Buyse
The Mayo/NCCTGExperience with 5-Fluorouracil and Leucovorin in Adjuvant Advanced Colorectal Cancer
Charles Erlichman, Richard M. Goldberg, and Daniel J. Sargent
Fluoropyrimidines for the Adjuvant Treatment of Colorectal Cancer: The NSABP Experience
Roy E. Smith, Eleftherios P. Mamounas, and Norman Wolmark
Clinical Trials of UFT Leucovorin in Gastrointestinal Malignancies
Paulo M. Hoff and Everardo D. Saad
The Development of Oral UFT with and without Leucovorin
Geert H. Blijham
UFT in Elderly Patients with Colorectal Cancer
Albert Abad and Jose Luis Manzano
Clinical Trials of the Eniluracil/5-Fluorouracil Combination
Hedy L. Kindler and Richard L. Schilsky
Discovery and Preclinical Pharmacology of Capecitabine
Hideo Ishitsuka
Capecitabine, A Tumor-Targeting Oral Fluoropyrimidine: Molecular Rationale and Clinical Validation
Dvorit Samid
Capecitabine: A Rationally Developed Anticancer Drug
Daniel R. Budman
Preclinical and Clinical Practice of S-1 in Japan
Tetsuhiko Shirasaka and Tetsuo Taguchi
Preclinical and Clinical Practice of Low-Dose FP Therapy in Japan: Japanese Use of Low-Dose FP Therapy
Tetsuhiko Shirasaka, Akihito Tsuji, Susumu Yamamitsu, and Tetsuo Taguchi
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2010
Pages: 338
Weight: 647g
Availability: Available
Subcategories: Oncology
From the same series
